APO RESEARCH · REPORT
Gabapentin
Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain.
Product & engineering
Understand the product.
Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain.
Selected research
Industry Research
Gabapentin Industry Research Report 2026
Market perspective
Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain.
Global Gabapentin key players include Novartis, TEVA, Mylan, Pfizer, etc. Global top four manufacturers hold a share about 20%.
North America is the largest market, with a share over 30%, followed by Asia-Pacific, and Europe, both have a share about 50 percent.
Read the full market overview
In terms of product, Capsule is the largest segment, with a share about 55%. And in terms of application, the largest application is Epilepsy, followed by Neuropathic Pain, Restless Legs Syndrome, etc.
Report Scope
This report quantifies the global Gabapentin market in terms of revenue (US$ million) and, where applicable, sales volume (M Unit), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Unit) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gabapentin Market by Company
Pfizer
Assertio Therapeutics
TEVA
Mylan
Arbor Pharma
Novartis
Apotex
Sun Pharmaceutical
Aurobindo Pharma
Intas
Amneal
Marksans Pharma
Glenmark
Alkem
Jiangsu Enhua
Jiangsu Hengrui
Sailike
Gabapentin Segment by Type
Capsule
Tablet
Gabapentin Segment by Application
Epilepsy
Neuropathic Pain
Restless Legs Syndrome
Others
Gabapentin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gabapentin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gabapentin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gabapentin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Gabapentin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Gabapentin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Gabapentin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Capsule
- Tablet
Applications
- Epilepsy
- Neuropathic Pain
- Restless Legs Syndrome
- Others
Companies covered
- Pfizer
- Assertio Therapeutics
- TEVA
- Mylan
- Arbor Pharma
- Novartis
- Apotex
- Sun Pharmaceutical
- Aurobindo Pharma
- Intas
- Amneal
- Marksans Pharma
- Glenmark
- Alkem
- Jiangsu Enhua
- Jiangsu Hengrui
- Sailike
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Gabapentin Market Size (2021-2032)
- 2.2.2 Global Gabapentin Sales (2021-2032)
- 2.2.3 Global Gabapentin Market Average Price (2021-2032)
- 2.3 Gabapentin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Capsule
- 2.3.3 Tablet
- 2.4 Gabapentin by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Epilepsy
- 2.4.3 Neuropathic Pain
- 2.4.4 Restless Legs Syndrome
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Gabapentin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Gabapentin Sales (M Unit) of Manufacturers (2021-2026)
- 3.3 Global Gabapentin Revenue of Manufacturers (2021-2026)
- 3.4 Global Gabapentin Average Price by Manufacturers (2021-2026)
- 3.5 Global Gabapentin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Gabapentin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Gabapentin, Product Type & Application
- 3.8 Global Manufacturers of Gabapentin, Established Date
- 3.9 Global Gabapentin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Pfizer
- 4.1.1 Pfizer Company Information
- 4.1.2 Pfizer Business Overview
- 4.1.3 Pfizer Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Pfizer Gabapentin Product Portfolio
- 4.1.5 Pfizer Recent Developments
- 4.2 Assertio Therapeutics
- 4.2.1 Assertio Therapeutics Company Information
- 4.2.2 Assertio Therapeutics Business Overview
- 4.2.3 Assertio Therapeutics Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Assertio Therapeutics Gabapentin Product Portfolio
- 4.2.5 Assertio Therapeutics Recent Developments
- 4.3 TEVA
- 4.3.1 TEVA Company Information
- 4.3.2 TEVA Business Overview
- 4.3.3 TEVA Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 TEVA Gabapentin Product Portfolio
- 4.3.5 TEVA Recent Developments
- 4.4 Mylan
- 4.4.1 Mylan Company Information
- 4.4.2 Mylan Business Overview
- 4.4.3 Mylan Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mylan Gabapentin Product Portfolio
- 4.4.5 Mylan Recent Developments
- 4.5 Arbor Pharma
- 4.5.1 Arbor Pharma Company Information
- 4.5.2 Arbor Pharma Business Overview
- 4.5.3 Arbor Pharma Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Arbor Pharma Gabapentin Product Portfolio
- 4.5.5 Arbor Pharma Recent Developments
- 4.6 Novartis
- 4.6.1 Novartis Company Information
- 4.6.2 Novartis Business Overview
- 4.6.3 Novartis Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novartis Gabapentin Product Portfolio
- 4.6.5 Novartis Recent Developments
- 4.7 Apotex
- 4.7.1 Apotex Company Information
- 4.7.2 Apotex Business Overview
- 4.7.3 Apotex Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Apotex Gabapentin Product Portfolio
- 4.7.5 Apotex Recent Developments
- 4.8 Sun Pharmaceutical
- 4.8.1 Sun Pharmaceutical Company Information
- 4.8.2 Sun Pharmaceutical Business Overview
- 4.8.3 Sun Pharmaceutical Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sun Pharmaceutical Gabapentin Product Portfolio
- 4.8.5 Sun Pharmaceutical Recent Developments
- 4.9 Aurobindo Pharma
- 4.9.1 Aurobindo Pharma Company Information
- 4.9.2 Aurobindo Pharma Business Overview
- 4.9.3 Aurobindo Pharma Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Aurobindo Pharma Gabapentin Product Portfolio
- 4.9.5 Aurobindo Pharma Recent Developments
- 4.10 Intas
- 4.10.1 Intas Company Information
- 4.10.2 Intas Business Overview
- 4.10.3 Intas Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Intas Gabapentin Product Portfolio
- 4.10.5 Intas Recent Developments
- 4.11 Amneal
- 4.11.1 Amneal Company Information
- 4.11.2 Amneal Business Overview
- 4.11.3 Amneal Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Amneal Gabapentin Product Portfolio
- 4.11.5 Amneal Recent Developments
- 4.12 Marksans Pharma
- 4.12.1 Marksans Pharma Company Information
- 4.12.2 Marksans Pharma Business Overview
- 4.12.3 Marksans Pharma Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Marksans Pharma Gabapentin Product Portfolio
- 4.12.5 Marksans Pharma Recent Developments
- 4.13 Glenmark
- 4.13.1 Glenmark Company Information
- 4.13.2 Glenmark Business Overview
- 4.13.3 Glenmark Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Glenmark Gabapentin Product Portfolio
- 4.13.5 Glenmark Recent Developments
- 4.14 Alkem
- 4.14.1 Alkem Company Information
- 4.14.2 Alkem Business Overview
- 4.14.3 Alkem Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Alkem Gabapentin Product Portfolio
- 4.14.5 Alkem Recent Developments
- 4.15 Jiangsu Enhua
- 4.15.1 Jiangsu Enhua Company Information
- 4.15.2 Jiangsu Enhua Business Overview
- 4.15.3 Jiangsu Enhua Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Jiangsu Enhua Gabapentin Product Portfolio
- 4.15.5 Jiangsu Enhua Recent Developments
- 4.16 Jiangsu Hengrui
- 4.16.1 Jiangsu Hengrui Company Information
- 4.16.2 Jiangsu Hengrui Business Overview
- 4.16.3 Jiangsu Hengrui Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Jiangsu Hengrui Gabapentin Product Portfolio
- 4.16.5 Jiangsu Hengrui Recent Developments
- 4.17 Sailike
- 4.17.1 Sailike Company Information
- 4.17.2 Sailike Business Overview
- 4.17.3 Sailike Gabapentin Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Sailike Gabapentin Product Portfolio
- 4.17.5 Sailike Recent Developments
5 Global Gabapentin Market Scenario by Region
- 5.1 Global Gabapentin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Gabapentin Sales by Region: 2021-2032
- 5.2.1 Global Gabapentin Sales by Region: 2021-2026
- 5.2.2 Global Gabapentin Sales by Region: 2027-2032
- 5.3 Global Gabapentin Revenue by Region: 2021-2032
- 5.3.1 Global Gabapentin Revenue by Region: 2021-2026
- 5.3.2 Global Gabapentin Revenue by Region: 2027-2032
- 5.4 North America Gabapentin Market Facts & Figures by Country
- 5.4.1 North America Gabapentin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Gabapentin Sales by Country (2021-2032)
- 5.4.3 North America Gabapentin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Gabapentin Market Facts & Figures by Country
- 5.5.1 Europe Gabapentin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Gabapentin Sales by Country (2021-2032)
- 5.5.3 Europe Gabapentin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Gabapentin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Gabapentin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Gabapentin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Gabapentin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Gabapentin Market Facts & Figures by Country
- 5.7.1 South America Gabapentin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Gabapentin Sales by Country (2021-2032)
- 5.7.3 South America Gabapentin Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Gabapentin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Gabapentin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Gabapentin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Gabapentin Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Gabapentin Sales by Type (2021-2032)
- 6.1.1 Global Gabapentin Sales by Type (2021-2032) & (M Unit)
- 6.1.2 Global Gabapentin Sales Market Share by Type (2021-2032)
- 6.2 Global Gabapentin Revenue by Type (2021-2032)
- 6.2.1 Global Gabapentin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Gabapentin Revenue Market Share by Type (2021-2032)
- 6.3 Global Gabapentin Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Gabapentin Sales by Application (2021-2032)
- 7.1.1 Global Gabapentin Sales by Application (2021-2032) & (M Unit)
- 7.1.2 Global Gabapentin Sales Market Share by Application (2021-2032)
- 7.2 Global Gabapentin Revenue by Application (2021-2032)
- 7.2.1 Global Gabapentin Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Gabapentin Revenue Market Share by Application (2021-2032)
- 7.3 Global Gabapentin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Gabapentin Value Chain Analysis
- 8.1.1 Gabapentin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Gabapentin Production Mode & Process
- 8.2 Gabapentin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Gabapentin Distributors
- 8.2.3 Gabapentin Customers
9 Global Gabapentin Analyzing Market Dynamics
- 9.1 Gabapentin Industry Trends
- 9.2 Gabapentin Industry Drivers
- 9.3 Gabapentin Industry Opportunities and Challenges
- 9.4 Gabapentin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst